Recent Updates
Recently added Catalysts

Brexanolone

Phase 4FDA approved

Alcohol Use Disorder (AUD) | Small Molecules | Psychiatry |Sage Therapeutics, Inc.|Trials Updated: Sep 21, 2026

Brexanolone development status

FDA approval on record Mar 19, 2019 as Zulresso
Approval holderSage Therap
ApplicationNDA211371
Highest phase Phase 4 (NCT04273191)
Phase scored for SAGEPhase 2
Registered trials 8 across 5 sponsors since Sep 2018

Brexanolone target and mechanism

Molecular targetGABRA1, GABRB2, GABRG2, GABRB3, GABRA4, GABRG3
Target classPositive Allosteric Modulator
ModalitySmall Molecules

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Brexanolone clinical trials

Brexanolone · 1 trial · 2 indications

Phase 2 1
NCT06580444Pregnenolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding StudyAlcohol Use Disorder (AUD)
NOT YET_RECRUITING40 Analytics
PHASE2NOT YET_RECRUITING
Pregnenolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Alcohol Use Disorder (AUD)Unlock trial analytics

Study Endpoints

Primary Endpoints

Severity and numbers of treatment-emergent AEs
From onset of Brexanolone administration until 30-day follow up.

The number and proportion of individuals experiencing any adverse event, any SAE, and any related adverse event overall will be summarized using frequency tables. No formal statistical tests will be conducted, rather the safety will be evaluated from a risk/benefit perspective. Any p-values reported will be for descriptive purposes only.

Change in Heart Rate from onset of Brexanolone administration until discharge from the drug administration session.
An average of 22 hours (From the start of Brexanolone administration on day 1 at 10 am until 7 am on day 2)

The change in heart rate a physiological safety/stress measure are continuous and obtained multiple times after study drug administration which occurs on day 1. This measure will be analyzed using descriptive statistics and graphical summaries including time-specific summary statistics (e.g., box and whisker plots).

Change in Blood Pressure from onset of Brexanolone administration until discharge from the drug administration session.
An average of 22 hours (From the start of Brexanolone administration on day 1 at 10 am until 7 am on day 2)

The change in blood pressure a physiological safety/stress measure are continuous and obtained multiple times after study drug administration which occurs on day 2. This measure will be analyzed using descriptive statistics and graphical summaries including time-specific summary statistics (e.g., box and whisker plots).

Change in Cortisol from onset of Brexanolone administration until discharge from the drug administration session.
FAn average of 22 hours (From the start of Brexanolone administration on day 1 at 10 am until 7 am on day 2)

The change in Cortisol a physiological safety/stress measure are continuous and obtained multiple times after study drug administration which occurs on day 2. This measure will be analyzed using descriptive statistics and graphical summaries including time-specific summary statistics (e.g., box and whisker plots).

Change in percentage of milliliters of alcohol consumed during the 2-hour ad-libitum drinking paradigm between laboratory sessions (stress vs. neutral).
During the 2-hour ad-libitum drinking paradigm between lab sessions (stress Vs Neutral)

A set of dose-response models will be tested response using the Multiple Comparisons Procedure Modifications (MCP-Mod) methodology including change in percentage of milliliters consumed during the 2-hour ad-libitum drinking paradigm within laboratory sessions (stress and neutral) as dependent variable, the treatment as factor (90, 60, 30 and 0 mcg/kg/h), and baseline dependent value. These dose-response models with repeated measures will be used to test the effects of the regimens of 90, 60, and 30 mcg/kg/h doses of brexanolone on alcohol consumption in self-administration.

Change in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score from intake until 30-day follow-up
From intake, day 0 through day 37 (30-day follow-up).

Another set of dose-response models will test Multiple Comparisons Procedure Modifications (MCP-Mod) methodology for the 30-day follow-up in PCL-5 score as dependent variable, the treatment as factor (90, 60, 30 and 0 mcg/kg/h), and baseline dependent value. These dose-response models will be used to test the effects of the regimens of 90, 60, 30 and 0 mcg/kg/h doses of brexanolone on PTSD symptoms. Scale PCL-5 is 0-4 with 0 being not at all and 4 being extreme; the higher score is worse outcome

Change in Change in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score from intake until end of dosing.
An average of 22 hours (From intake, day 0 through end of infusion on Day 2)

Another set of dose-response models will test Multiple Comparisons Procedure Modifications (MCP-Mod) methodology including change from intake to end of dosing in PCL-5 score as dependent variable, the treatment as factor (90, 60, 30 and 0 mcg/kg/h), and baseline dependent value. The same modeling will be repeated for the 30-day follow-up timepoint. These dose-response models will be used to test the effects of the regimens of 90, 60, 30 and 0 mcg/kg/h doses of brexanolone on PTSD symptoms. Scale PCL-5 is 0-4 with 0 being not at all and 4 being extreme; the higher score is worse outcome

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeOTHER

Treatment Arms

ArmTypeDescription
PlaceboNO_INTERVENTIONA 0.9% bag of sodium chloride will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
90mcg/kg/h dose of BrexanoloneACTIVE_COMPARATORBrexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
60mcg/kg/h dose of BrexanoloneACTIVE_COMPARATORBrexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.
30mcg/kg/h dose of BrexanoloneACTIVE_COMPARATORBrexanolone will be diluted with sterile water and 0.9% sodium chloride and will be administered intravenously. Participant will be given a self-administered alcoholic drink of their choice that is individually calculated, and they will receive money up to $15 for every minute they resist drinking.

Interventions

NameTypeDescription
BrexanoloneDRUGThe participant will receive either a placebo, or 90, 60, or 30 mcg/kg/hr of Brexanolone over a 20-hour period intravenous infusion.
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 70 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: 1. Provision of signed and dated informed consent form. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged 21-70 years old, either active duty or with a history of US military service. 4. Current DSM-...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMNov 10, 2026NCT06580444primaryCompletionDate: changed
MEDIUMNov 10, 2026NCT06580444primaryCompletionDate: changed
MEDIUMNov 10, 2026NCT06580444primaryCompletionDate: changed

Frequently asked questions about Brexanolone

What is brexanolone?

Brexanolone is a small-molecule drug being studied by Sage Therapeutics for Alcohol Use Disorder. It acts as a positive allosteric modulator at GABA-A receptor subunits including GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It is investigational and is in Phase 2 clinical development for this indication.

What is brexanolone used for in Alcohol Use Disorder?

Brexanolone is being developed for Alcohol Use Disorder, a psychiatry indication. A Phase 2 study is also evaluating it in veterans with concurrent Alcohol Use Disorder and Post Traumatic Stress Disorder. It has not been established as a treatment outside of clinical research.

What does brexanolone target?

Brexanolone targets GABA-A receptor subunits, specifically GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It is classified as a positive allosteric modulator, meaning it enhances GABA-A receptor activity. This mechanism underlies its investigation in Alcohol Use Disorder.

Who is developing brexanolone?

Brexanolone is being developed by Sage Therapeutics, Inc., which trades under the ticker SAGE. Sage is the sponsor of the clinical program evaluating brexanolone in Alcohol Use Disorder and related psychiatric conditions.

What phase is brexanolone in?

Brexanolone is in Phase 2 clinical development for Alcohol Use Disorder. It is investigational and has not completed a pivotal program for this indication. The current Phase 2 study is active but not yet recruiting participants.

What clinical trials is brexanolone in?

Brexanolone is being studied in trial NCT06580444, a Phase 2 dose-finding study in veterans with concurrent Alcohol Use Disorder and Post Traumatic Stress Disorder. The trial is randomized, double-blind, and active-controlled, with an planned enrollment of 40 participants aged 21 and older.